Abstract | Sickle cell disease (SCD) substantially alters renal structure and function, and causes various renal syndromes and diseases. Such diverse renal outcomes reflect the uniquely complex vascular pathobiology of SCD and the propensity of red blood cells to sickle in the renal medulla because of its hypoxic, acidotic, and hyperosmolar conditions. Renal complications and involvement in sickle cell nephropathy (SCN) include altered haemodynamics, hypertrophy, assorted glomerulopathies, chronic kidney disease, acute kidney injury, impaired urinary concentrating ability, distal nephron dysfunction, haematuria, and increased risks of urinary tract infections and renal medullary carcinoma. SCN largely reflects an underlying vasculopathy characterized by cortical hyperperfusion, medullary hypoperfusion, and an increased, stress-induced vasoconstrictive response. Renal involvement is usually more severe in homozygous disease (sickle cell anaemia, HbSS) than in compound heterozygous types of SCD (for example HbSC and HbSβ + -thalassaemia), and is typically mild, albeit prevalent, in the heterozygous state (sickle cell trait, HbAS). Renal involvement contributes substantially to the diminished life expectancy of patients with SCD, accounting for 16-18% of mortality. As improved clinical care promotes survival into adulthood, SCN imposes a growing burden on both individual health and health system costs. This Review addresses the renal manifestations of SCD and focuses on their underlying mechanisms.
Introduction
Few diseases give rise to such diverse renal manifesta tions as does sickle cell disease (SCD). Such involvement adversely affects virtually all major physiological pro cesses in the kidney, and leads to complications that are common and chronic on the one hand (such as impaired urinary concentrating ability), and those that are rare and uniformly fatal on the other (such as renal medul lary carcinoma). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Box 1 summarizes the spectrum of manifestations and processes that characterize sickle cell nephropathy (SCN).
Renal involvement can occur throughout the life of a patient with SCD. Manifestations such as hyperfiltration, hypertrophy, and impaired urinary concentrating ability are described as early as in infancy. Microalbuminuria is observed in some patients in childhood, whereas haema turia and acute kidney injury (AKI) can occur at any age. Macroalbuminuria tends to occur in early to middle adulthood, and can be accompanied by regression of the glomerular filtration rate (GFR) to the normal range. In the later decades, the risk of chronic kidney disease (CKD), progressive reduction of GFR, and endstage renal disease (ESRD) increases.
This steady, agedependent accrual of adverse renal sequelae shortens the average lifespan of patients with SCD. Proteinuria and a reduced GFR are risk factors associated with increased mortality among patients with SCD; [16] [17] [18] approximately 16-18% of overall mortal ity in this patient group is ascribed to kidney disease. 19, 20 Once ESRD is reached, the mortality of patients who are on haemodialysis and have SCD is increased several fold relative to the mortality of patients who are on haemo dialysis but do not have SCD. 21 Thus, although the average lifespan of patients with SCD has increased during recent decades owing to improved management of complications outside the kidney, the agedependent accrual of kidney disease contributes substantially to the still increased mortality in SCD.
Prefaced by an overview of SCD, this Review addresses renal manifestations in SCD and their underlying pathogenetic mechanisms.
Overview of SCD
SCD is one of the most frequent hereditary haematologic diseases in the world. Its most severe and common form, sickle cell anaemia (SCA), results from homozygosity for the mutant form of the gene that encodes βglobin. SCA is also the most severe form of SCD in terms of its renal manifestations. These renal manifestations are generally less severe in the compound heterozygous forms of SCD (such as HbSC and HbSβ + thalassaemia), and are comparatively mild in the heterozygous state, sickle cell trait (SCT). The current global population of patients with SCD is substantial: in 2010, SCT afflicted approximately 5.5 million neonates, and 312,000 neo nates were born with SCA. 22 In the coming decades, this worldwide burden is expected to markedly increase, 23 thereby underscoring the importance of gaining a full understanding of the renal complications of SCD. Mutant sickle βglobin results from substitution of valine for glutamic acid at its sixth amino acid. The resulting sickle haemoglobin (HbS) polymerizes when the concentration of its deoxygenated form (deoxyHbS) Key points ■ Sickle cell nephropathy (SCN) largely reflects an underlying renal vasculopathy characterized by the coexistence of cortical hyperperfusion, medullary hypoperfusion, and an increased renal vasoconstrictive response to systemic and regional stress ■ Renal involvement is usually more severe in sickle cell anaemia (HbSS) than in other types of sickle cell disease (HbSC and HbSβ + -thalassaemia), and is typically mildest in sickle cell trait ■ Proteinuria and decreased glomerular filtration rate are independent risk factors for increased mortality in sickle cell disease; 16-18% of overall mortality is estimated to arise from kidney disease ■ The most frequent glomerulopathy in SCD is focal segmental glomerulosclerosis, a lesion considered to be mediated by alterations in glomerular haemodynamics ■ Haematuria and loss of concentrating ability are among the most frequent renal syndromes caused by sickle cell disease, both of which are also common in sickle cell trait ■ Angiotensin-converting-enzyme inhibitor therapy is recommended for patients with SCN and microalbuminuria and proteinuria, even in the presence of normal blood pressure exceeds a critical threshold. Thus, polymerization is governed by local oxygen tension, and promoted by both acidosis (which decreases the affinity of HbS for oxygen) and hyperosmolarity (which increases red blood cell [RBC] haemoglobin [Hb] concentration). Additionally, sickle RBCs exhibit abnormally high adhe sion to the endothelium, owing to acquired membrane changes and to retained adhesion receptors on reticulo cytes, especially the stress reticulocytes. This adhesion event slows microvascular transit, thereby enabling the sickling process. 24, 25 The ambient conditions of the renal medulla promote polymerization of HbS. The medullary milieu is hypoxic and acidotic, and its hyperosmolality dehydrates the RBC, thereby increasing the intracellular concentration of HbS. Moreover, the relatively slow blood flow in the vasa recta prolongs RBC transit through the medulla, thereby increasing the propensity for polymerization of HbS. Finally, slow vasa recta blood flow would promote RBC adhesion to the endothelium, as such adhesion can be enhanced by low shear stress.
Vascular stasis induces ischaemia that can progress to infarction. Alternatively, vascular stasis can resolve, leading to ischaemia-reperfusion and accompanying processes such as oxidative stress and inflammation. Ischaemia-reperfusion pathobiology in SCD is unique, in that occlusions are generally microvascular, multi focal, and recurrent. 26 All these processes are relevant to the renal complications of SCD, as are other processes such as endothelial activation and dysfunction, aberrant vascular reactivity, nitric oxide (NO) deficiency, haemolysis, and procoagulant processes (Figure 1 ). 8, 13 Renal vasculopathy in SCD Vasculopathies can arise from either functional or structural changes in the vasculature. The presence of a renal vasculopathy in SCD is indicated by alterations in renal haemodynamics. These alterations accompany changes in the systemic circulation, and underlie the patho genesis of most manifestations of SCN. As noted in a previous review, SCD exhibits a "perfusion paradox" that is charac terized by "a curious coexistence of con trasting perfusion profiles in the circulatory system: hypoperfusion is endemic in microcirculatory beds occluded by haemoglobin Scontaining erythrocytes while hyper perfusion characterizes the systemic (macro) circulation and a number of regional vascular circuits. " 8 In young patients (generally those in the late teens to early thirties) who have SCD without major organ damage, plasma volume and cardiac output are higher than in healthy individuals; as systemic blood pres sure in these patients is usually lower than in healthy individuals, systemic vascular resistance is diminished. Hyperperfusion, which occurs systemically, also occurs regionally; blood flow is increased in the forearm, pedal cutaneous area, brain, and kidney. 8, 27 The combination of the hyperperfused whole kidney and the micro circulatory regional defects in the renal medulla thus exemplifies, in a single organ, the perfusion paradox in SCD. 
REVIEWS
Increased renal plasma flow in SCD is accompanied by increased renal blood flow and GFR. 28, 29 This supra normal GFR subsides to a normal GFR with either ageing or development of CKD, and to a subnormal GFR as CKD progresses. Hyperfiltration can occur as early as in infancy in patients with SCD, 30 and is also exhib ited in transgenic murine models of SCD. 31 Filtration fraction is reduced in patients with SCD, and this obser vation might reflect the selective loss of juxtamedullary nephrons, which exhibit a higher filtration fraction than do cortical nephrons.
Wholekidney GFR is the sum of GFRs in all functional nephrons. If one assumes that the number of nephrons in the kidney of a patient with SCD is unchanged from that of healthy individuals, then the increased whole kidney GFR observed in SCD reflects increased single nephron GFR (SNGFR). SNGFR is determined by glomerular plasma flow rate, the transcapillary hydraulic pressure gradient, the glomerular ultrafiltration coeffi cient (K f ), and plasma oncotic pressure. 32 In young adults who have SCD and exhibit renal hyperperfusion and hyperfiltration, functional measurements and mathemat ical modelling demonstrate that hyperfiltration is princi pally driven by increased glomerular plasma flow rate and K f ; elevations in transcapillary hydraulic pressure gradient values are marginal. 33 Haemodynamic alterations in SCD are assigned considerable importance in the pathogenesis of glomerular disease in SCN, as discussed below.
K f is of interest in SCD for at least two additional reasons. First, K f is the product of the total filtering surface area and the glomerular hydraulic permeability; glomerular hypertrophy has long been recognized as a feature of SCD, and an increased K f value might reflect an increased filtering surface area. Second, the decline in GFR to a normal level as albuminuria occurs and to a sub normal level with the development of CKD partly reflects a progressive decrease in K f . 34 The basis for renal hyperperfusion remains unre solved. Such hyperperfusion cannot be readily ascribed to anaemia or increased plasma volume because correc tion of anaemia by HbAcontaining RBC transfusions does not reverse hyperperfusion, 35 and chronic anaemia from causes other than SCD is not usually associated with renal hyperperfusion. 36 Hyperperfusion likely reflects the activity of vasorelaxant species, especially because renal vascular resistance (RVR) is reduced. 8 Such vasorelaxant species include prostaglandins, the production of which increases in the kidney of patients with SCD, possibly because of medullary ischaemia. 3 Although NO is also implicated in hyperperfusion, no evidence to date demonstrates an increase in RVR when NO synthase (NOS) isoforms are inhibited. Indeed, SCD is commonly viewed as a state characterized by a defi ciency of and/or resistance to NO. Increased production of kallikrein might also underlie renal hyperperfusion. 37 A possible basis for renal hyperperfusion involves the haem oxygenase-carbon monoxide (HO-CO) system. In SCD, haem oxygenase (HO1 protein) is induced in the kidney and other organs, 38 in the vasculature, 38 in circu lating leucocytes, 39 and in circulating endothelial cells. 38 Such induction is likely driven by haem, oxidative stress, and inflammation. Markedly increased systemic levels of CO (a vasorelaxant product of HO) reflect the induction of HO1 in the kidney, vasculature, other tissues, and cir culating cells. 40, 41 Induction of HO-CO might contribute to systemic hyperperfusion and to regional hyperperfusion of the kidney and other vascular beds. Moreover, as previ ously suggested, 13 COdriven vasodilatation could explain the puzzling association of hyperfiltration (which is usually associated with renal vasodilatation) with haemolysis (which is usually associated with vasoconstriction because of NO binding by haemoglobin) described in SCD. 42 In contrast to wholekidney blood flow, medullary blood flow is regarded as being markedly reduced in SCD. This consensus is based on prominent vasa recta vasoocclusion observed on histological examination and in classical microangiographic studies in humans. 43 These studies demonstrate marked loss of vasa recta that supply the inner medulla, and abrupt termination and distortion of the few remaining vasa recta. 43 Older studies that were based on renal extraction of paraaminohippurate and which suggest that medullary blood flow is increased 29 are uninterpretable because such extraction does not reliably reflect medullary blood flow when wholekidney blood flow is increased. This vascular stasis explains why RBC sickling occurs in the microcirculation, despite the fact that the time required for sickling usually exceeds RBC transit through the microcirculation. Additional pathobiological pathways include haemolysis and increased free plasma haemoglobin. Plasma haemoglobin scavenges NO from the endothelium. Autoxidation and degradation of HbS lead to the release of free haem, which is toxic to the endothelium via its pro-oxidant and proinflammatory properties. Abbreviations: deoxyHbS, deoxygenated HbS; HbS, sickle haemoglobin; NO, nitric oxide; pO 2 , partial pressure of oxygen; RBC, red blood cell; WBC, white blood cell.
Pathogenesis of SCN
A functional renal vasculopathy sets the stage for SCN; hyperperfusion underlies many of the observed cortical changes, and hypoperfusion underlies changes in the medulla ( Figure 2 ). Aberrant renal vascular responses to stress occur in SCD, leading to exaggerated renal vasoconstriction. Cyclical episodes of renal ischaemia and ischaemia-reperfusion predispose to recurrent subclinical and clinical AKI ( Figure 2 ). The key ele ments in this synthesis of the pathogenesis of SCN are discussed below.
Increased renal growth
Increased renal growth occurs in SCD, but the reasons are unclear. 1, 44 This increased growth can be observed as early as in infancy, when renal enlargement cor relates with hyperfiltration. 30, 45 Interestingly, SCD is one of several conditions in which increased renal growth accompanies hyperperfusion; the other con ditions include the remnant kidney, diabetes mellitus, pregnancy, and increased dietary protein intake. 32, [46] [47] [48] The 'renal work hypothesis' provides an explana tion for the association of increased renal blood flow with kidney size in these conditions, and might also apply to SCD. This hypothesis proposes that altera tion of renal haemodynamics leads to increased renal growth: 46 hyperperfusion driven hyperfiltration delivers increased amounts of salt and water to the proximal tubule, which increases tubular reabsorp tion of sodium and water to restore glomerulotubular balance. Proximal tubular reabsorption of sodium is the main determinant of renal oxygen consumption, which increases to sustain increased tubular transport of sodium. This demand for increased renal metabolic work stimulates the requisite mitochondrial processes and adaptive cellular responses, culminating in proximal tubular and overall renal enlargement. Systemic levels of assorted growth factors are also elevated in SCD, 49 and these growth factors might exert nephrotrophic effects.
Glomerular enlargement in disease models com monly accompanies increased glomerular plasma flow rates and intraglomerular pressure, 32, 47 in a process similar to the hypertrophy of blood vessels that are sub jected to increased blood flow and pressure. This complex phenomenon might be relevant to the glomerular hypertrophy that occurs in SCD.
Glomerular and other histologic lesions
Renal histologic findings in SCD include congestion of the cortical and glomerular capillaries, mesangial prolif eration, thickening and reduplication of the glomerular basement membrane, glomerulosclerosis, tubular depo sition of iron, congestion of the vasa recta, interstitial oedema, tubulointerstitial inflammation, and fibro sis.
1,50-54 Focal segmental glomerulosclerosis (FSGS) and its variants are the major glomerular lesions in SCD. [55] [56] [57] Histologic patterns such as membranoproliferative glo merulonephritis and thrombotic microangiopathy occur less frequently than FSGS, and immune reactants, when detected, are usually considered nonspecific.
Proteinuria and chronic kidney disease
Proteinuria is agedependent in SCD. When assessed either as microalbuminuria (30-300 mg/g creatinine) or macroalbuminuria (>300 mg/g creatinine), and as comprehensively reviewed in 2014, 15 proteinuria occurs in up to 27% of patients in the first three decades, 15, 58 and in up to 68% of older patients. 15, 59 The natural history of CKD in SCD remains poorly defined, par ticularly the extent to which microalbuminuria pro gresses to macroalbuminuria, and macroalbuminuria progresses to nephroticrange proteinuria. Albuminuria levels >500 mg/g creatinine are associated with progres sive CKD, as shown in a retrospective study that involved 98 patients over 5 years. 60 In this study, the prevalence of CKD rose from 29% to 42% over this period, and the prevalence of patients with CKD in stages 1, 2, 4, and 5 increased. 60 Nephroticrange proteinuria occurs in 4% of patients with SCD and presages progressive CKD. 61 Prior studies demonstrate that irreversible kidney damage (defined by a serum creatinine level >132.6 μmol/l) occurs in approximately 12% of patients with SCD. 62 Proteinuria and/or CKD are associated with a number of factors in addition to older age, and variably so depending upon the study. These factors are prehyper tensive blood pressure profiles, 63 increased blood pres sure, [64] [65] [66] parvovirus B19. 76 Development of SCN is thus complex, as it can be influenced by blood pressure, haematologic profiles, inflammation, assorted extrarenal processes, and vasoocclusive disease in distant organs.
Albuminuria is usually more severe in SCA than in other types of SCD, and is more likely to occur in patients who express specific single nucleotide polymorphisms in the MYH9 and APOL1 genes, which are associated with an increased risk of CKD in African Americans. 77 Conversely, microdeletions in the gene that encodes αglobin (reflecting a form of αthalassaemia trait) leads to a lower prevalence of macroalbuminuria among patients with SCA. 78 Genetic polymorphisms of bone morphogenetic protein receptor 1B also influence GFR in SCA. 79 Defects in glomerular permselectivity exist in patients who have SCD with proteinuria, as shown by frac tional clearance of IgG and neutral dextran sieving. 33, 34 In patients with proteinuria and in whom GFR is either increased or within the normal range, the radius of restrictive pores in the glomerular filtration barrier is increased; 33, 34 in patients with proteinuria and reduced GFR, macromolecular flux through the shunt pathway is substantially increased. 34 Interestingly, patients with albuminuria and SCD exhibit increased urinary excre tion of markers of tubular injury (KIM1 and NAG). 80 Whether such findings reflect tubular injury induced by glomerular proteinuria or tubular injury as a con tributor to impaired tubular albumin reabsorption is largely unaddressed.
Angiotensinconvertingenzyme inhibitors are employed to reduce proteinuria and delay the progres sion of CKD in patients with SCD. 55 Although this approach has not been vigorously tested in patients with SCD, 81 it is recommended on the basis of the general effi cacy of these agents in CKD. Recommendations made by an expert panel in 2014 include the initiation of treat ment with these agents in patients with microalbumin uria and macroalbuminuria, even when blood pressure is normal. 82 Interest also surrounds the use of hydroxy urea, as such treatment diminishes renal enlargement and improves urinary concentrating ability in infants, 83 decreases glomerular hyperfiltration in children, 84 and is associated with less albuminuria in adults. 75 Acute kidney injury AKI occurs in 4-10% of hospitalized patients with SCD, and is more frequent in patients with acute chest syndrome (13.6%) than in patients with painful crisis (2.3%). 85, 86 AKI is prognostically important in SCD, as it predicts a less favourable outcome among patients who are transferred to the intensive care unit. 87 AKI devel ops in some 75% of episodes of painful crisis that are complicated by acute multiorgan failure; haemodialysis is needed during 18% of these episodes. 88 In prospec tively studied patients, a reversible 15% reduction in cre atinine clearance occurs during painful crisis. 89 Even in patients with painful crisis but a normal serum creatin ine level (an imperfect marker of GFR in SCD because of the relatively high tubular secretion of creatinine), acute subclinical tubular injury occurs, as evidenced by more than a twofold increase in urinary excretion of NGAL. 90 Factors that predispose to AKI include volume depletion, rhabdomyolysis, infections, and the use of nonsteroidal analgaesics.
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Pathogenesis of progressive CKD CKD progresses because of interactions among multi ple processes in the vascular, glomerular, tubular, and interstitial compartments of the kidney. 91, 92 Information regarding such processes in SCN is limited; the following sections broadly outline possible pathogenetic pathways relevant to progressive SCN.
Haemodynamic glomerular injury SNGFR and glomerular plasma flow rate are predicted to increase in SCD, along with marginal increases in glomerular capillary pressure. As shown by substantial experimental data, these haemodynamic alterations can damage the glomerular endothelium, the podocyte, and the glomerular filtration barrier, thereby causing protein uria; proteinuria extends injury into the tubulointerstitial compartment. 7, 32, 47, 91 Damage to podocytes leads to focal adhesions to the parietal epithelium. 93 These adhesions cause FSGS, the misdirection of glomerular filtration, and the development of interstitial inflammation.
Increased glomerular growth
Glomerular enlargement is considered a precursor of glomerular injury. 32, 47 Glomerular enlargement increases wall tension in the capillary loops, even when intra glomerular pressure is unchanged, in accordance with Laplace's Law (which states that wall tension in spherical objects is the product of intraluminal pressure and radius of the sphere). 47 Increased wall tension might damage the glomerular endothelium, the podocyte, and the filtra tion barrier in SCD. Additionally, if hypertrophy of the podocyte does not proceed at the same pace as the glo merular enlargement, areas of the glomerular basement membrane will be bereft of podocyte foot processes; these denuded areas adhere to the parietal epithelium, thereby predisposing to FSGS.
Endothelium-podocyte/pericyte crosstalk
Podocyte integrity-the main determinant of glomerular permselectivity-is critically dependent upon a healthy glomerular endothelium. 94 Endothelial integrity is, in turn, dependent upon podocytederived signals. For example, vascular endothelial growth factor (VEGF), which is produced by podocytes, maintains the health of the neighbouring endothelium through endothelial production of NO and other mechanisms. Abundant evidence for endothelial dysfunction in SCD exists; 8, 13 indeed, such evidence is fundamental to the concept of SCD as a vasculopathic state. 95, 96 The same dysfunction in the glomerular endothelium would promote an activated, proinflammatory, and procoagulant endothelial pheno type; inflammatory mediators (such as endothelin 1 [ET1] and tumour necrosis factor) from the glomeru lar endothelium would, in turn, engage receptors on podocytes, thereby causing podocyte injury and pro teinuria. Additionally, the procoagulant endothelial phenotype would promote formation of microthrombi in the capillary loops. Such pathogenetic processes orig inating in the dysfunctional glomerular endo thelium could thus contribute to histologic lesions such as FSGS, membranoproliferative glomerulonephritis, and thrombotic microangiopathy.
Studies of soluble fmslike tyrosine kinase 1 (sFLT1) in SCD provide new insights into endothelial dysfunc tion in SCD and its relevance to glomerular injury. 74 sFLT-1 binds VEGF and disrupts the trophic effects of VEGF on the endothelium, thereby leading to endo thelial dysfunction. Plasma levels of sFLT-1 are increased in SCD, and might thereby predispose to albuminuria. 74 Endothelial dysfunction in SCD could also result from the prooxidant effects of ET1 and the binding of NO by HbS, as plasma levels of both ET1 and HbS are elevated in SCD.
A healthy endothelium is necessary for the normal behaviour of pericytes. Pericytes regulate medullary blood flow in the healthy kidney, and transform into myofibroblasts in the diseased kidney; chronic tubulo interstitial disease is largely driven by myofibroblast pro liferation and migration. 92, 97 Endothelial dysfunction in SCD might perturb the behaviour of pericytes, leading to impaired medullary blood flow and transformation of pericytes into myofibroblasts, thus setting the stage for CKD.
Haemolysis-induced renal injury
Haemolysis prominently occurs in SCD. Free plasma HbS, which is not haptoglobinbound, exists as dimers that readily traverse the glomerular filtration barrier. Haemoglobinuria leads to tubular incorporation of HbS followed by intracellular breakdown of HbS and haem. Iron thus accumulates in renal tubules and accounts for the clinical observation that renal iron content detected by MRI correlates with the severity of haemolysis. 98, 99 Several studies have shown an association of haem olysis with proteinuria and CKD, [69] [70] [71] and further observations indicate that CKD and its progression are associated with haemoglobinuria. 100 In one patient cohort, CKD and haemoglobinuria were present in 58% and 36% of patients, respectively; in another, they were present in 54% and 20% of patients, respectively. In both cohorts, haemoglobinuria independently associated with CKD. 100 Moreover, in a longitudinal analysis over 32 months, haemoglobinuria was associated with the progression of CKD. 100 Repetitive exposure of the kidney to haem proteins induces CKD; 101 the condition is exaggerated when haemdegrading capacity is impaired. 102 Renal sensi tivity to haemoglobin increases with age, 103 and age is a major risk factor for CKD among patients with SCD. Haemolysis can lead to renal injury in SCD through the following mechanisms. HbS is an unstable protein that undergoes autoxidation and denaturation to produce oxidants and free haem. Trafficking of HbS across podocytes and tubular epithelial cells can impose oxidantmediated cellular injury. Additionally, haem is a ligand for the Tolllike receptor 4, 104 which is present on endothelial, mesangial, and tubular epithelial cells, and on podocytes; proinflammatory responses in these cells can thus be triggered by haem. 105 Interestingly, haem promotes proliferation of smooth muscle cells, 106 which are phenotypically similar to mesangial cells. Mesangial trafficking of HbS and haem, along with mesangial phagocytosis of fragmented sickle RBCs, might under lie mesangial proliferation, which is often observed in SCD. Finally, the prooxidant effects of HbS and haem might upregulate proinflammatory and fibrogenic genes, leading to infiltrative and fibrosing processes in the glomerular and tubulointerstitial compartments.
Repetitive vascular and other acute insults
Repetitive but mild acute insults or a single severe acute insult to the kidney can cause CKD. 101, 107 This concept is especially applicable to SCN: SCD is characterized by intermittent episodes of vasoocclusion, and the kidney in SCD shows an increased susceptibility to a single acute insult. 108, 109 In a transgenic murine model of SCD, a relatively brief episode of acute renal ischaemia instigates a strik ing reduction in GFR, a marked increase in RVR, rapid extension of vascular congestion from the inner medulla into the cortex, tubular necrosis, and upregulation of pro inflammatory mediators such as tumour necrosis factor and inducible NOS;
108,109 induction of inducible NOS causes nitrosative stress and tubular damage, as shown in prior studies. 110 ATP is promptly depleted following ischaemia, thereby compromising homeostatic pro cesses, including those that phosphorylate and activate proteins that are critical for cell survival. 109 Interestingly, unilateral ischaemia exaggerates vaso occlusion in the contralateral, nonischaemic kidney, and bilateral renal ischaemia triggers vasoocclusion in the lungs. These findings indicate the propensity for localized renal injury to instigate vasoocclusion and resultant ischaemia in distant, previously nonischaemic microcirculatory beds in the kidney and elsewhere. 108 Vascular congestion and vasoocclusion, especially when repetitive, can promote CKD in at least four ways. First, vasoocclusion induces endothelial injury, which triggers the release of proinflammatory and profibrogenic cytokines. Second, vasoocclusion causes hypoxia in the cortex and medulla that, in turn, elicits hypoxiainducible factor1α (HIF1α)dependent and HIF1αindependent pathways of CKD. 111, 112 In CKD that develops independently of SCD, interstitial capil lary rare fraction in the diseased kidney causes renal hypoxia, which constitutes one of the final common pathways for progressive CKD. 113, 114 Thus, the origins of hypoxia and hypoxiadependent pathways of renal injury in SCN are at least twofold: vasoocclusion in SCD, and capillary rare fraction that occurs irrespective of cause. Third, sufficiently severe acute insults to the tubular epithelium can cause capillary rarefraction, interstitial disease, and glomerulosclerosis. 115 Fourth, the resolu tion of vasoocclusion ushers in ischaemia-reperfusion and accompanying pathobiological processes, including proinflammatory and profibrogenic pathways. 26, 108, 109 Contributors to renal vascular congestion and dys function during vasoocclusive disease include oxidative stress, 38 ET1, 116 thrombospondin, 117 and adenosine. 118 Even in steadystate SCD, when infection, pain and other disease are absent, plasma ET1 levels are increased, as is renal expression of preproET1 mRNA; ET1 recep tor blockers attenuate renal vascular congestion, inflam mation, and vasoconstriction induced by hypoxia. 116 During vasoocclusive episodes, thrombospondin levels increase in the plasma, where it promotes the shed ding of micro particles from RBCs; these microparticles induce oxidantmediated endothelial injury, increase RBC adhesion to the endothelium, and promote renal vasoocclusive disease. 117 Plasma levels of adenosine (an ATP breakdown product) are increased in steadystate SCD; adenosine promotes RBC sickling by increasing levels of 2,3diphosphoglycerate in RBCs. 118 Strategies that chronically reduce plasma adenosine levels also reduce renal vascular congestion, microinfarcts, histo logical injury and proteinuria, and increase urinary con centrating ability. 118 Interrupting these mediators of renal vasoocclusion thus provides a strategy for decreasing CKD in SCD.
Tubular hyperfunction
Increased GFR in SCD would, predictably, increase proximal tubular sodium reabsorption because of glo merulotubular balance. Hyperfunctioning of the proxi mal tubule exists in SCD, as evidenced by increased tubular reabsorption of β2microglobulin protein and phosphate (the latter being linked to sodium reabsorp tion); increased proximal tubular secretion of uric acid and creatinine; and increased transport maximum for para aminohippurate. Increased sodium reabsorption increases oxygen consumption, and such hypermetabo lism of renal tubules predisposes to tubulointerstitial injury through oxidative stress and other mechanisms. 119 Additionally, greater oxygen consumption during hypermetabolism might exacerbate renal hypoxia in SCD.
Other pathogenetic pathways
Clinical studies suggest that renal immune injury might result from tubular injury and resultant tubular antigen exposure, 120 and that glomerular injury might arise from ironmediated processes. 121 Experimental studies suggest that opiates also contribute to SCN. 122 Urinary concentrating defect Nephrogenic in origin, impaired urinary concentrat ing ability frequently occurs in SCD, and can appear as early as in infancy. 1, [3] [4] [5] 12 This impairment can lead to enuresis and polyuria, and increases the risk of dehydra tion. Before the age of 15 years, but not thereafter, this impairment can be corrected by repeated transfusions of HbAcontaining RBCs. 123 Adults with SCD can rarely achieve a urine osmolality greater than 450 mOsm/ kg following water restriction, and this impairment is vasopressinresistant.
3 Impaired free water reabsorption accompanies this loss of concentrating ability, whereas the diluting ability is intact. 3 RBC sickling and congestion in the vasa recta, and resultant ischaemia, impair both solute reabsorption by the ascending limb of the long loops of Henle and the capacity of the vasa recta to serve as countercurrent exchangers. 1, 3 These impairments lead to a decrease in solute accrual and retention in the medullary interstitium, thereby reducing interstitial osmolality. Reabsorption of water across antidiuretichormonestimulated collecting ducts is critically dependent upon interstitial osmolal ity; as the latter is reduced in SCD, concentrating ability is impaired. In time, recurrent cycles of ischaemia and infarction cause vasa recta rarefraction, the haphazard formation of collaterals, and loss of the long loops of Henle that descend into the inner medulla and papilla. 43 Such structural abnormalities underlie the failure to correct this impaired concentrating ability with HbAcontaining RBC transfusions later in life.
The preservation of diluting ability despite an impair ment of free water reabsorption in SCD draws upon the fact that the long loops of Henle that descend into the inner medulla and papilla derive from the juxta medullary nephrons, the efferent arterioles of which supply the accompanying vasa recta; 124 juxtamedullary nephrons represent approximately 15% of the nephron population. 85% of nephrons have short loops and peri tubular capillaries that descend no deeper than the outer medulla. Unlike the population of juxtamedul lary nephrons, this population of superficial nephrons escapes the damaging effects of vasoocclusion in the vasa recta (and are relatively intact prior to the development of CKD). The relative preservation of this nephron popu lation (85% of the total population) explains why dilut ing ability is intact, as this function is essentially carried out by the thick ascending limb. The preservation of this nephron population also explains why the upper limit of urinary concentration in adults with SCD is approxi mately 450 mOsm/kg, as this value is the osmolality achieved in the outer medulla. 3 
Haematuria
Haematuria is among the most common renal manifesta tions of SCD, and can present as microscopic or macro scopic haematuria; the latter can be lifethreatening. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] Haematuria reflects capillary congestion, especially in the medullary vessels, with extravasation of RBCs into the tubular lumen. Congestion and rupture of the sub mucosal capillaries in the renal pelvis can also be responsible for haematuria; these vessels branch from the efferent arteri oles of the juxtamedullary nephrons, from which the vasa recta also arise. 1, 3 Blockage of the vasa recta can divert blood flow to capillaries that supply the mucosa of the renal pelvis and to the peritubular capillaries of the juxta medullary nephrons. Haematuria emanates more fre quently from the left kidney than the right because of the socalled nutcracker phenomenon imposed upon the left renal vein as it passes between the aorta and the superior mesenteric artery; this phenomenon leads to compression of the vein.
Haematuria might also reflect the presence of renal papillary necrosis caused by vasoocclusion in the vasa recta. 9 Besides painless haematuria, renal papillary necrosis can also present with asymptomatic radio graphic findings, urinary tract obstruction and infection, and flank pain and fever.
In rare cases, haematuria is caused by renal medul lary carcinoma, a locally invasive, fastgrowing malig nancy that usually presents within the first few decades, and causes death within 2 years of diagnosis. 9 Reported cases predominantly involve SCT rather than SCA. This malignancy can present as haematuria, pain, a renal mass, or constitutional symptoms; its pathogenesis is essentially unknown. [125] [126] [127] Distal nephron dysfunction Impaired medullary perfusion in SCD can cause distal nephron dysfunction, which manifests as an acidification defect and/or an impaired ability to secrete potassium.
Earlier studies demonstrate the presence of an incom plete distal renal tubular acidosis (RTA) in steadystate SCD, with little apparent acid-base abnormality apart from a mild respiratory alkalosis in some patients. 1, 3, 4 Generation and maintenance of an adequate proton gradient for acid excretion are energydependent pro cesses that might be impaired by medullary ischaemia. Subsequent studies in 2014 emphasize the importance of RTA in SCD: retrospective analyses of over 400 patients demonstrate that more than 40% of patients with SCD exhibit a metabolic acidosis ascribed to an under lying normokalaemic RTA that arises from diminished availability of ammonium. 128 Impaired potassium excretion in SCD likely reflects resistance of the distal nephron to aldosterone. 129 Hyperkalaemic hyperchloraemic metabolic acidosis is also recognized in patients with SCD, and reflects either a type IV RTA defect or a selective aldosterone defi ciency. 130 Hyporeninaemic hypoaldosteronism can occur in SCD in rare cases. 130 Sickle cell trait In SCT, only 40% of RBC haemoglobin content is HbS: the rest is normal HbA. Nevertheless, this amount of HbS is sufficient to cause common complications such as haematuria and impaired concentrating ability. 131, 132 Renal microangiographic studies show distortion and destruction of the vasa recta in SCT, but considerably less than in SCD. 43 Volume contraction due to the urinary concentrating defect likely contributes to the increased risk of AKI, renal infarction, and rhabdomyolysis seen in these patients, especially under physical stress in hot and humid conditions. 131, 132 Considerable interest exists in whether the presence of SCT predisposes an individual to CKD. 132, 133 Evidence has been mixed: divergent conclusions were reached as to whether the prevalence of SCT is greater in African American patients with ESRD than in individuals without ESRD, 134, 135 and whether SCT increases the risk of proteinuria in individuals with diabetes mellitus. 136, 137 However, based on data from five populationbased prospective studies that involved a total of approximately 16,000 African Americans, a 2014 analysis demonstrated that SCT is clearly associated with an increased risk of CKD and a reduction in GFR. 138 Prior studies indicated that the presence of SCT in individuals with polycystic kidney disease predisposes them to ESRD. 139 SCT confers at least one benefit: a reduction in the severity of malaria and its complications. 140 Experimental studies demonstrate that such protection is conferred by the induction of HO1. 141 
Conclusions
A current paradigm for the renal complications of SCD is that medullary ischaemia induces synthesis of vaso dilatory prostaglandins, which elicit renal hyperperfu sion. 3 Medullary ischaemia also causes distal nephron dysfunction, which then instigates proximal tubular hyperfunction as a compensatory response. 3 The present Review takes into account the following considerations. First, the majority of renal complications of SCD result from an underlying functional vasculo pathy, in which renal hyperperfusion and medullary hypoperfusion (which together represent the renal perfusion paradox) occur concomitantly, rather than medullary hypoperfusion serving as the forerunner of renal hyperperfusion. 8 Second, renal hyperperfusion is an organspecific manifestation of an enhanced vaso dilatory response that is exhibited systemically and in specific regional beds in SCD, and one that conceivably underlies the low blood pressure and reduced preva lence of systemic hypertension in SCD. Third, renal hyper filtration increases proximal tubular transport to maintain glomerulotubular balance; hyperfunction of the proximal nephron is caused by hyperfiltration of the upstream glomerulus, rather than by hypofunctioning of the downstream distal nephron. 8 Fourth, increased glo merular size in SCD results from the sustained increase in glomerular perfusion, whereas increased renal meta bolic work might drive proximal tubular growth and con sequent kidney growth in SCD. Fifth, vascular instability exists in the kidney in SCD, as demonstrated by an exag gerated renal vasoconstrictive response to stress despite augmented vasorelaxation of the kidney in steadystate SCD. 8 Vasorelaxant systems, if maximally upregulated in steadystate SCD, might thus lack the functional reserve needed to counter vasoconstrictive stress imposed upon the kidney. 8 From a therapeutic standpoint, the kidney as an organ affected by SCD presents unique challenges. First, thera peutic approaches need to be cognizant of the marked heterogeneity of renal involvement on the one hand, but tailored to individual variability in specific renal mani festations on the other. Second, the natural history and pathobiology of some prominent renal manifestations of SCD, such as proteinuria, are still poorly understood. Current therapeutic approaches are largely adopted from other kidney diseases 82 without being specifically geared to either the milieu or nuances of SCD. Third, interrup tion of a given pathophysiologic system could exert diver gent effects that mitigate the severity of one manifestation but exacerbate the severity of another. For example, the renin-angiotensin system contributes to FSGS in a murine model of SCD but reduces the severity of the con centrating defect; interruption of the renin-angiotensin system-a frequently employed therapeutic approach in SCD-might therefore protect against one renal com plication but exacerbate the other. 142 Fourth, the sickle milieu causes a multitude of pathobiologic processes, and the relative contributions of these processes to the renal complications of SCD are still being defined. Although no allencompassing solution exists for these challenges, one general approach worth consideration is a multimodal therapeutic strategy that seeks to interrupt the critical steps in salient pathogenetic pathways. 143 
